Podbit · Moonshots with Peter Diamandis
Returning humans to the Moon by 2028, building the first elements of a lunar base by 2030, and launching a nuclear reactor into space — all within the current administration's timeline. Kratsios frames these as the Apollo-era national missions needed to inspire a new generation into STEM.
Where this was said
At 16:25 · chapter starts 15:05
Peter asks Kratsios to paint the long-term vision for America, pushing beyond incremental healthcare wins. Kratsios frames his answer in terms of national missions — bold, specific goals that generate national pride and inspire young people the way Apollo once did. [1] — Michael Kratsios "Returning humans to the Moon by 2028, building the first elements of a lunar base by 2030, and launching a nuclear reactor into space — all…" 16:25 The list is staggering: humans on the Moon in 2028, the first elements of a lunar base by 2030, a nuclear reactor in space (with Mars propulsion capability) by 2028, a scientifically relevant quantum computer by the end of the president's term (directed through executive order), and an evolving national fusion strategy backed by more private investment than at any point in history — including 37 venture-backed fusion companies. Kratsios is most personally excited about quantum's applications in pharmaceuticals, where the ability to model molecular interactions could be transformational. The conversation reveals a government that is, for the first time in decades, willing to stake out ambitious, falsifiable timelines for moonshot-level achievements.
The administration's space missions include returning humans to the Moon by 2028, building the first lunar base elements by 2030, and launching a nuclear reactor in space by 2028.
Peter Diamandis counted 37 venture-backed fusion energy companies currently operating, reflecting unprecedented private-sector investment in the space.
Social norms compress behavior so effectively that we assume other minds are similar to ours. They almost never are. After running over 100 psychology studies, Greenberg's biggest finding is that humans are far more different from each other than we intuitively believe.
The widely shared claim that we have a credit card's worth of plastic in our brains may be a massive overestimate. Researchers used nitrile gloves to measure microplastics — and nitrile gloves shed microplastic particles onto the measuring device. A second paper found the original tool used was unreliable, and that we may have far less plastic than reported.
RSD isn't just hurt feelings — it's a dopamine-deficient brain with a hyperactive amygdala and a frayed connection to the prefrontal cortex. Add a surge of norepinephrine and you get chest pain, sweating, and trembling that convinces your body something catastrophic is happening.
In Dan Ariely's door experiment, participants sacrificed the highest-reward door — repeatedly — just to avoid seeing other doors disappear. Even when researchers trained them to use the best door, they kept wasting clicks to maintain options. This is the bias that runs our lives: we'll take a worse outcome to preserve the feeling of optionality.
Dan Gilbert discovered that the brain has a 'psychological immune system' — it misremembers, reframes, and rationalizes to keep you satisfied with whatever you chose. The fear before commitment is all about potential regret. But after committing, your brain quietly starts justifying the choice — and the more irreversible the decision, the stronger the effect.
The psychological immune system can get you through the first few months of any commitment. But durable, long-term well-being requires self-concordance — choosing commitments that are genuinely aligned with your values and what you actually want. Without that alignment, the satisfaction fades fast.
Vision didn't just help animals find food — it ignited the Cambrian explosion of speciation. Half of the human cortex is devoted to visual processing, and that same visual hierarchy directly inspired the neural network architectures powering today's AI.
Peptides come loaded with a powerful narrative: regenerative, subcutaneous, targeted, cutting-edge. That narrative can genuinely move outcomes, especially for pain, energy, and recovery. The RCT's job is to quantify how much additional benefit comes from the molecule itself — above and beyond the compelling story surrounding it.
A pharmaceutical is not an amino acid sequence — it is the successful solution to manufacturing, purification, formulation, and consistency challenges. When clinical trials prove a drug works, they validate a specific product under specific processes, not every preparation that shares the same sequence.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.